Search

Your search keyword '"Scoccimarro, Erika"' showing total 30 results
Start Over Author "Scoccimarro, Erika" Publication Year Range Last 10 years
30 results on '"Scoccimarro, Erika"'

2. Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience

Author

Francolini, Giulio, Campi, Riccardo, Di Cataldo, Vanessa, Detti, Beatrice, Loi, Mauro, Triggiani, Luca, La Mattina, Salvatore, Borghetti, Paolo, Magrini, Stefano Maria, Nicosia, Luca, Alongi, Filippo, Ghirardelli, Paolo, Vavassori, Vittorio, Allegra, Andrea Gaetano, Aquilano, Michele, Scoccimarro, Erika, Peruzzi, Anna, Pastina, Pierpaolo, Visani, Luca, Desideri, Isacco, Serni, Sergio, Meattini, Icro, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

3. Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)

Author

Meattini, Icro, Francolini, Giulio, Di Cataldo, Vanessa, Visani, Luca, Becherini, Carlotta, Scoccimarro, Erika, Salvestrini, Viola, Bellini, Chiara, Masi, Laura, Doro, Raffaela, Di Naro, Federica, Loi, Mauro, Salvatore, Giulia, Simontacchi, Gabriele, Greto, Daniela, Bernini, Marco, Nori, Jacopo, Orzalesi, Lorenzo, Bianchi, Simonetta, Mangoni, Monica, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

4. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery

Author

Scoccianti, Silvia, Perna, Marco, Olmetto, Emanuela, Delli Paoli, Camilla, Terziani, Francesca, Ciccone, Lucia Pia, Detti, Beatrice, Greto, Daniela, Simontacchi, Gabriele, Grassi, Roberta, Scoccimarro, Erika, Bonomo, Pierluigi, Mangoni, Monica, Desideri, Isacco, Di Cataldo, Vanessa, Vernaleone, Marco, Casati, Marta, Pallotta, Stefania, and Livi, Lorenzo

Published
2021
Full Text
View/download PDF

8. 3089: LOCAL CONTROL AND LONG TERM TOXICITY IN SPINAL METASTASES TREATED WITH SRT

Author

Carnevale, Maria Grazia, Loi, Mauro, Simontacchi, Gabriele, Lorenzetti, Victoria, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Visani, Luca, DiCataldo, Vanessa, Salvestrini, Viola, Bonomo, Pierluigi, Peruzzi, Anna, Bettazzi, Beatrice, Valzano, Marianna, Casati, Marta, Arilli, Chiara, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

9. 2793: Clinical and toxicity outcomes with preoperative radiation therapy in a large cohort of STS patients

Author

Loi, Mauro, Greto, Daniela, Banini, Marco, Valzano, Marianna, Romei, Andrea, Morelli, Ilaria, Bonaparte, Ilaria, Simontacchi, Gabriele, Becherini, Carlotta, Scoccimarro, Erika, Francolini, Giulio, Salvestrini, Viola, Bonomo, Pierluigi, Peruzzi, Anna, Pallotta, Stefania, Roselli, Giuliana, Campanacci, Domenico, Guido, Scoccianti, Annarita, Palomba, Mangoni, Monica, Meattini, Icro, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

10. 2178: Role of ablative regimen and prior chemotherapy in liver metastases treated with SBRT

Author

Valzano, Marianna, Banini, Marco, Loi, Mauro, Bonomo, Pierluigi, Simontacchi, Gabriele, Galardi, Alessandra, Becherini, Carlotta, Greto, Daniela, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Mangoni, Monica, Di Cataldo, Vanessa, Salvestrini, Viola, Mattioli, Chiara, Angelini, Lucia, Caprara, Luisa, Zani, Margherita, Marrazzo, Livia, Masi, Laura, Doro, Raffaella, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

11. 2105: Pregnancy in BRCA-carrier patients after breast cancer therapy: single-centre real-world experience

Author

Bettazzi, Beatrice, Visani, Luca, Gensini, Francesca, Olmetto, Emanuela, Garlatti, Pietro, Desideri, Isacco, Scoccimarro, Erika, Di Cataldo, Vanessa, Bonomo, Pierluigi, Peruzzi, Anna, Frosini, Giulio, Caprara, Luisa, Valzano, Marianna, Bernini, Marco, Orzalesi, Lorenzo, Nori, Jacopo, Bianchi, Simonetta, Becherini, Carlotta, Salvestrini, Viola, Livi, Lorenzo, and Meattini, Icro

Published
2024
Full Text
View/download PDF

12. 1442: EBUS-guided fiducial placement for SBRT in mediastinal nodal oligometastases

Author

Morelli, Ilaria, Dieng, Oulimata, Loi, Mauro, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Valzano, Marianna, Visani, Luca, Di Cataldo, Vanessa, Salvestrini, Viola, Luzzi, Valentina, Tomassetti, Sara, Doro, Raffaella, Masi, Laura, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

13. Abstract PD3-03: Preoperative robotic radiosurgery for early breast cancer: results of the phase II ROCK trial (NCT03520894)

Author

Meattini, Icro, primary, Francolini, Giulio, additional, Cataldo, Vanessa Di, additional, Visani, Luca, additional, Becherini, Carlotta, additional, Scoccimarro, Erika, additional, Mangoni, Monica, additional, Salvestrini, Viola, additional, Masi, Laura, additional, Bellini, Chiara, additional, Doro, Raffaela, additional, Naro, Federica Di, additional, Bernini, Marco, additional, Nori, Jacopo, additional, Orzalesi, Lorenzo, additional, Bianchi, Simonetta, additional, and Livi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

16. 2888: Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients

Author

Visani, Luca, Ratosa, Ivica, Ribnikar, Domen, Becherini, Carlotta, Bertini, Niccolò, Bonaparte, Ilaria, Stefanovski, Dimitar, Dobnikar, Nika, Desideri, Isacco, Olmetto, Emanuela, Mangoni, Monica, Di Cataldo, Vanessa, Peruzzi, Anna, Mattioli, Chiara, Cela, Doruntina, Valzano, Marianna, Salvestrini, Viola, Scoccimarro, Erika, Livi, Lorenzo, and Meattini, Icro

Published
2024
Full Text
View/download PDF

17. 1439: Comparing toxicity in soft tissue sarcoma: preoperative radio-chemotherapy vs radiotherapy alone

Author

Greto, Daniela, Loi, Mauro, Banini, Marco, Romei, Andrea, Morelli, Ilaria, Bonaparte, Ilaria, Campanacci, Domenico Andrea, Scoccianti, Guido, Roselli, Giuliana, Palomba, Annarita, Simontacchi, Gabriele, Becherini, Carlotta, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, and Livi, Lorenzo

Published
2024
Full Text
View/download PDF

19. Regorafenib in glioblastoma recurrence: A case report

Author

Detti, Beatrice, primary, Scoccianti, Silvia, additional, Lucidi, Sara, additional, Maragna, Virginia, additional, Teriaca, Maria Ausilia, additional, Ganovelli, Michele, additional, Desideri, Isacco, additional, Lorenzetti, Victoria, additional, Scoccimarro, Erika, additional, Greto, Daniela, additional, and Livi, Lorenzo, additional

Published
2021
Full Text
View/download PDF

20. Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).

Author

Meattini, Icro, primary, Scoccimarro, Erika, additional, Saieva, Calogero, additional, Desideri, Isacco, additional, Visani, Luca, additional, Dominici, Luca, additional, Cerbai, Cecilia, additional, Aquilano, Michele, additional, Ciccone, Lucia Pia, additional, Palmieri, Valeria Emma, additional, Scotti, Vieri, additional, Nori, Jacopo, additional, Bernini, Marco, additional, Orzalesi, Lorenzo, additional, Sanchez, Luis, additional, Dieci, Maria Vittoria, additional, Bianchi, Simonetta, additional, and Livi, Lorenzo, additional

Published
2020
Full Text
View/download PDF

22. Preoperative robotic stereotactic radiotherapy in early breast cancer: Phase II ROCK trial (NCT03520894).

Author

Visani, Luca, Salvestrini, Viola, Meattini, Icro, Becherini, Carlotta, Desideri, Isacco, Scoccimarro, Erika, Cataldo, Vanessa Di, Mangoni, Monica, Bellini, Chiara, Nori, Jacopo, Bernini, Marco, Orzalesi, Lorenzo, Sanchez, Luis, Bianchi, Simonetta, Doro, Raffaella, Masi, Laura, and Livi, Lorenzo

Subjects
RADIOTHERAPY, STEREOTACTIC radiotherapy, BREAST cancer, HORMONE receptor positive breast cancer, MAGNETIC resonance imaging, LUMPECTOMY, RECTAL cancer, CANCER relapse
Abstract

Background: Breast-conserving surgery (BCS) followed by postoperative radiation therapy (RT) to the residual breast represents the current standard of care for most women affected by early breast cancer. However, standard postoperative regimens are characterized by postsurgical waiting time and potential acute and late locoregional adverse events. Several studies suggested that breast cancer cells can be more sensitive to high doses administered in short intervals. Preoperative robotic stereotactic radiotherapy (SBRT) followed by BCS may yield potential advantages in selected patients. An exploratory phase II study (ROCK trial – NCT03520894) was conducted in our institution. Materials: Women with histologically proven unifocal invasive hormonal receptors positive, HER2 negative breast cancer, sized less than 25 mm, with negative clinical nodal status, aged 50+ and eligible for BCS were enrolled. Fiducial markers were introduced in peri/ intralesional position. Magnetic resonance imaging (MRI) was used in addition to standard CT-based planning. Patients received 21 Gy in single fraction with CyberKnife® followed by BCS two weeks after preoperative SBRT. The primary endpoint was the acute skin toxic effect rate. Secondary objectives were the pathological response rate and the late adverse events rate. Echocardiography and spirometry were performed before preoperative SBRT and yearly thereafter. Translational research was conducted to identify correlations between radiogenomic, immunological and biochemical biomarkers with treatment-related response and toxicity. Results: From August 2018 to September 2021, a total of 70 patients were screened on mammography; 29 of them were eligible following inclusion criteria. Seven were excluded due to multiple foci disease at basal MRI, and 22 patients were successfully treated. All required dosimetric parameters and normal tissue constraints were met in all cases. Median age at diagnosis was 68 years (range 50-86) and median tumor size was 13 mm (range 7.5-25). All treated patients received surgery within 14 days from preoperative SBRT without any delay or complication. No patients experienced acute skin toxicity of grade (G) 2 or higher; only one patient had a G1 erythema one month after BCS. Two patients reported a pathological complete response, according to Chevallier’s classification. At a median follow up of 18 months, no patients experienced locoregional recurrence or distant metastases. No clinically meaningful changes were observed regarding left-ventricular ejection fraction and spirometric parameters. Conclusion: Results from the ROCK trial showed that single fraction preoperative robotic SBRT is a feasible technique in selected breast cancer patients with a good safety profile and encouraging activity. This new approach warrants further investigations. [ABSTRACT FROM AUTHOR]

Published
2022

23. Efficacy of stereotactic radiotherapy in patients with oligometastatic iodinerefractory thyroid cancer.

Author

Simontacchi, Gabriele, Scoccimarro, Erika, Valzano, Marianna, Lucidi, Sara, Mangoni, Monica, Sparano, Clotilde, and Livi, Lorenzo

Subjects
*THYROID cancer, *STEREOTACTIC radiotherapy, *PROGRESSION-free survival, *PROTEIN-tyrosine kinase inhibitors, *OVERALL survival, *CANCER patients
Abstract

Differentiated thyroid cancer is usually associated with a good prognosis. The development of metastases in Iodine-refractory thyroid cancer adversely affect patients’ quality of life and survival. The advent of tyrosine-kinase inhibitors drugs (TKI) allowed a great improvement of patients’ outcome but, in case of oligometastatic disease, a locoregional ablative approach such as Stereotactic Radiation Therapy (SRT) could effectively control tumour progression and possibly defer the need of systemic therapies. In our study, we analysed the effectiveness of SRT in oligometastatic Iodine-refractory thyroid cancer patients. Methods: We retrospectively analysed patients with differentiated oligometastatic thyroid cancer treated with SRT in our Radiation Oncology Unit from 2011 to 2020. We collected demographics and treatment-related characteristics. Local Control (LC), Progression Free Survival (PFS) and Overall Survival (OS) rates were evaluated. Patients with anaplastic histology, incomplete treatment or without follow-up information were excluded. Results: We retrospective analysed a cohort of 15 patients, aged between 47 and 72 years old (median 63,3). 8 (53,3%) patients were males and 7 (46,7%) were females. A total of 42 lesions were treated: 19 were located in bones (45,2%), 11 in lymph nodes (26,2%), 3 visceral (7.1%), 7 in the brain (16,7%) and 2 in the lungs (4,8%). SBRT was delivered in 1-8 fractions, with a median dose of 30Gy (range 14-60Gy). Median followup from the date of the first SRT was 47,7 months (range 14,4–105 months). After SRT we observed a complete response in 21 lesions (50%), partial response in 13 (31%), stable disease in 7 (16,7%) and only 1 progressive lesion (2,4%). We observed 9 local recurrences (21,4%) with an actuarial LC of 95% and 89,9% at 12 and 24 months respectively, while PFS was 45.6% and 32,9% at 12 and 24 months respectively. The OS at 12, 24, 48 months was 93,3%, 86,2% and 79%, respectively. A total number of 10 patients (66,7%) underwent TKI treatment (4 Sunitinib and 5 Lenvatinib) for progressive disease: median time to first systemic treatment from the SBRT was 17,7 months (range 1-47,7 months). At the end of this analysis, 5 patients (33.3%) were still without systemic therapy, showing a good disease control after a median follow-up of 50,6 months (range 35.3-57). Conclusions: In our experience, SRT yields satisfying local control rates in oligometastatic Iodine-refractory thyroid cancer, allowing for a deferral of systemic therapies. [ABSTRACT FROM AUTHOR]

Published
2022

24. 2872: Predictors of pCR in Neoadjuvant Treatment for Locally Advanced Rectal Cancer.

Author

Bettazzi, Beatrice, Carnevale, Maria G., Loi, Mauro, Bonomo, Pierluigi, Galardi, Alessandra, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Scoccimarro, Erika, Francolini, Giulio, Desideri, Isacco, Mangoni, Monica, Di Cataldo, Vanessa, Salvestrini, Viola, Frosini, Giulio, Angelini, Lucia, Bertini, Niccolò, Banini, Marco, Talamonti, Cinzia, and Livi, Lorenzo

Subjects
*NEOADJUVANT chemotherapy, *RECTAL cancer
Published
2024
Full Text
View/download PDF

27. 1121: Examining clinical outcomes and toxicities in definitive chemoradiation for carcinoma of anal canal.

Author

Romei, Andrea, Galardi, Alessandra, Simontacchi, Gabriele, Becherini, Carlotta, Greto, Daniela, Olmetto, Emanuela, Garlatti, pietro, Scoccimarro, Erika, Visani, Luca, Bonomo, Pierluigi, Peruzzi, Anna, Meattini, Icro, Desideri, Isacco, Mangoni, Monica, Banini, Marco, Talamonti, Cinzia, and Livi, Lorenzo

Subjects
*ANUS, *TREATMENT effectiveness, *CHEMORADIOTHERAPY, *CARCINOMA
Published
2024
Full Text
View/download PDF

28. 1122: Chemotherapy regimens with definitive radiotherapy in Squamous Cell Carcinoma of the Anal Canal.

Author

Romei, Andrea, Lucidi, Sara, Greto, Daniela, Olmetto, Emanuela, Garlatti, Pietro, Meattini, Icro, Scoccimarro, Erika, Francolini, Giulio, Visani, Luca, Mangoni, Monica, Bonomo, Pierluigi, Loi, Mauro, Peruzzi, Anna, Frosini, Giulio, Cela, Dora, Bertini, Niccolò, and Livi, Lorenzo

Subjects
*ANUS, *SQUAMOUS cell carcinoma, *RADIOTHERAPY, *CANCER chemotherapy
Published
2024
Full Text
View/download PDF

29. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.

Author

Visani, Luca, Livi, Lorenzo, Ratosa, Ivica, Orazem, Miha, Ribnikar, Domen, Saieva, Calogero, Becherini, Carlotta, Salvestrini, Viola, Scoccimarro, Erika, Valzano, Marianna, Cerbai, Cecilia, Desideri, Isacco, Bernini, Marco, Orzalesi, Lorenzo, Nori, Jacopo, Bianchi, Simonetta, Morandi, Andrea, and Meattini, Icro

Subjects
*METASTATIC breast cancer, *CYCLIN-dependent kinase inhibitors, *EPIDERMAL growth factor receptors, *RADIOTHERAPY, *TERMINATION of treatment, *CYCLIN-dependent kinases
Abstract

• CDK4/6 inhibitors represent the standard-of-care for metastatic HR+/HER2 breast cancer. • Available data on CDK4/6 inhibitors and concomitant RT are conflicting. • We showed that concurrent RT did not increase treatments severe toxicity. • A consensus guideline to help physician's routine practice is strongly needed. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for the initial treatment of patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The aim of our study is to evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the metastatic setting. From September 2017 to February 2020, we retrospectively collected and analysed data on a sequential series of patients treated with CDK4/6i, receiving RT or not, at two European institutions. Primary outcome of the study was the association between RT and any adverse events (AEs) ≥ G3. Secondary outcomes were the association between RT and any AEs (any grade), CDK4/6i dose reduction rate, and CDK4/6i treatment discontinuation rate. We analysed a total of 132 consecutive women; RT was prescribed in 57 (43.2%) patients (70 irradiated lesions). The median age of the series was 52.1 years (range 32.3–78.2). Concomitant RT administration was not significantly related to higher AEs ≥ G3 (p = 0.19) and any grade AEs (p = 1.0); there was no association with RT and CDK4/6i dose reduction (p = 0.49) and discontinuation rates (p = 0.14). At a median follow-up of 18.8 months, the progression-free survival (PFS) rate was 35% and the overall survival (OS) rate was 38.7% in the whole group. The use of concomitant RT did not affect both PFS (p = 0.71) and OS rates (p = 0.55). Our data are encouraging regarding the safety of this combination, showing that concurrent RT did not increase severe toxicity and did not have an impact on systemic treatment conduction. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration

Author

Pier Luigi Meroni, Irene Pontikaki, Rolando Cimaz, Andrea Taddio, E. Scoccimarro, Teresa Giani, Giovanna Ferrara, Gabriele Simonini, Simonini, Gabriele, Ferrara, Giovanna, Pontikaki, Irene, Scoccimarro, Erika, Giani, Teresa, Taddio, Andrea, Meroni, Pier Luigi, and Cimaz, Rolando

Subjects
Male, medicine.medical_specialty, Time Factors, Wilcoxon signed-rank test, Adolescent, Arthritis, Disease, biologic therapies, flare, juvenile idiopathic arthritis, remission duration, 03 medical and health sciences, 0302 clinical medicine, juvenile idiopathic arthriti, Rheumatology, Recurrence, Internal medicine, medicine, Humans, 030212 general & internal medicine, Child, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, Proportional hazards model, business.industry, Biologic therapies, Remission Induction, Retrospective cohort study, biologic therapie, medicine.disease, Arthritis, Juvenile, Surgery, Exact test, Treatment Outcome, Withholding Treatment, Antirheumatic Agents, Child, Preschool, Remission duration, Female, business
Abstract

OBJECTIVE: to assess the time in remission after discontinuing biologic therapy in JIA patients. METHODS: we enrolled 135 patients followed in three tertiary care centers. Primary outcome was to assess, once remission was achieved, the time in remission up to the first flare after discontinuing treatment. Mann-Whitney U-test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher's exact test were used to compare data. Pearson and Spearman correlation tests were used to determine correlation coefficients for different variables. In order to identify predictors of outcome Cox regression model and Kaplan-Meier curves were constructed, each one at mean of entered covariates. RESULTS: The majority of enrolled patients flared after stopping treatment with biologics (102/135, 75.6%) after a median follow-up time in remission off therapy of 6 months (range 3-109). A higher probability of maintaining remission after discontinuing treatment was present in systemic onset disease compared to the rest of JIA patients (Mantel-Cox χ2 8.31, p 2 years after achieving remission had a higher probability of maintaining such remission off therapy (18.64 ±3.3 months vs 11.51 ±2.7, p

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results